| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 2.52 | 41.6% | 39.2% |
| Total Income | 2.52 | 41.6% | 39.2% |
| Expenditure | 15.57 | 5.2% | 51.6% |
| PBT | — | ||
| Net Profit | -12.71 | 3.4% | 61.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.17 | 34.6% | 6.3% |
InspireMD Reports Q3 2025 Revenue Up 39% to $2.5 Million
04 May 2026 · 4 May, 8:16 am
Summary
InspireMD reported a 39% increase in revenue for the third quarter of 2025, reaching $2.5 million. The growth was driven by the U.S. commercial launch of CGuard Prime and increased penetration in international markets. Gross profit also increased to $864,000 due to higher revenue and a favorable sales mix. The company's cash and cash equivalents and marketable securities totaled $63.4 million as of September 30, 2025.
Key Highlights
- 1
InspireMD's total revenue increased by 39% to $2.5 million in the third quarter of 2025, compared to $1.8 million in the same period last year.
- 2
U.S. revenue for the third quarter was $497,000, while international revenue reached $2.0 million.
- 3
Gross profit for the third quarter of 2025 increased to $864,000, a $450,000 increase compared to $414,000 for the third quarter of 2024.
- 4
The company initiated the U.S. commercial launch of the CGuard Prime carotid stent system.
- 5
InspireMD completed over 100 U.S. carotid procedures across leading hospitals.
- 6
As of September 30, 2025, cash and cash equivalents and marketable securities were $63.4 million compared to $34.6 million as of December 31, 2024.
- 7
Net loss for the third quarter of 2025 was $12.7 million, or $0.17 per basic and diluted share.
Management Comments
Marvin Slosman
Our business demonstrated strong growth across all geographies in the third quarter of 2025. Over the last few months, our team executed our planned U.S. commercial launch of our CGuard Prime carotid stent system, which delivered measurable revenue in our initial commercial quarter in the United States. We continue to see strong demand for our solutions globally, validating our mission as we work to transform the carotid intervention market with a stent first approach. Further, with the addition of $58 million in gross proceeds to our balance sheet, as announced in July, we are able to continue adding top-tier talent and executing our commercial rollout with intention, purpose, and stamina. We are entering a new era of growth, and I am confident that this team and technology can deliver immense value over the years ahead.”
Informational and educational content only. Not investment advice.